Results from a trial of natalizumab in secondary progressive MS suggest anti-inflammatory treatments could slow disability accumulation, even after significant function has been lost.
Swedish study favours rituximab over fingolimod for those at risk of progressive multifocal leukoencephalopathy
French researchers compare oral and injectable drugs for relapsing-remitting MS
Switching from natalizumab to an alternative drug may prevent disease reactivation
A method for early detection of Natalizumab-associated progressive multifocal leukoencephalopathy in the absence of clinical symptoms
Study shows that switching to natalizumab is more effective than switching to fingolimod
Natalizumab is associated with clinically meaningful improvements in walking speeds
The new test measures the risk of PML infection in people being treated with Natalizumab